Growth Opportunities in Gene Therapy to Transform Short Bowel Syndrome Treatment

Short Bowel Syndrome Market


The Short Bowel Syndrome Market is estimated to be valued at US$ 188.9 Bn in 2023 and is expected to exhibit a CAGR of 11.5% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.


Market Overview:



Short bowel syndrome is a malabsorptive disorder that occurs when the small intestine does not absorb enough nutrients and water from food. It is a condition usually caused by surgical removal of part of the small intestine, resulting in problems with digestion and absorption of nutrients. SBS patients require parenteral nutrition support for survival.


Market Dynamics:



The short bowel syndrome market is primarily driven by two key factors:

High cost of immunotherapy treatment: Immunotherapy drugs used for treating short bowel syndrome come with a heavy price tag which limits their widespread adoption. For instance, Teduglutide costs over $300,000 annually per patient in the US. This high cost poses significant barriers for patients.

Side effects of immunotherapy drugs: Drugs used for short bowel syndrome often cause unpleasant and sometimes severe side effects. Teduglutide treatment can lead to abdominal pain, vomiting, nausea, diarrhea and injection site reactions. The interference of side effects with daily life discourages patients from opting for immunotherapy.

Market key trends:



The global Short Bowel Syndrome market has been witnessing increasing adoption of parenteral nutrition as a standard treatment option. Parenteral nutrition helps supplement nutrition in patients who cannot eat sufficiently due to intestinal failure caused by short bowel syndrome. The market has also observed growth in small bowel transplantation procedures over the past few years. Research involving intestinal stem cell therapy holds promise to accelerate bowel growth in patients and eventually eliminate the need for parenteral support and nutrition.


SWOT Analysis


Strength: High unmet medical needs and limited treatment options present lucrative growth opportunities.
Weakness: Risks and complications associated with parenteral nutrition and small bowel transplant procedures.
Opportunity: Significant research into new drug therapies, gut modulators, growth factors, and regenerative medicine approaches.
Threats: High cost of immunotherapy treatment, side effects of immunotherapy drugs.

Key Takeaways

The Global Short Bowel Syndrome Market Size is expected to witness high growth, exhibiting CAGR of 11.5% over the forecast period of 2023-2030, due to increasing research and development of novel therapeutics. The market size in 2023 is US$ 188.9 Bn.

Regional analysis: North America currently dominates the global market due to rising prevalence of intestinal disorders and technological advancements. However, Asia Pacific is expected to grow at fastest pace due to rising healthcare spending and expanding medical tourism industry.

Key players operating in the Short Bowel Syndrome market include Shire Plc., Merck & Co., Inc., Real Food Blends, LLC, VectivBio AG, Ardelyx, Inc., Zealand Pharma A/S, GLyPharma Therapeutic, Inc., Naia Pharmaceuticals, Inc., and others.

Key players analysis: Key players operating in the Short Bowel Syndrome market include Shire Plc., Merck & Co., Inc., Real Food Blends, LLC, VectivBio AG, Ardelyx, Inc., Zealand Pharma A/S, GLyPharma Therapeutic, Inc., Naia Pharmaceuticals, Inc.



Read More - https://www.insightprobing.com/short-bowel-syndrome-market-share-trends-forecasts-growth-and-size-analysis/

Comments

Post a Comment

Popular posts from this blog

Riding the Wave: Navigating Dynamics in the Windsurf Foil Board Market

Image
   Windsurf Foil Board Market In the exhilarating world of water sports, the Windsurf Foil Board Market emerges as a key player, offering enthusiasts innovative equipment to enhance their riding experience. As this niche market continues to gain traction among windsurfing aficionados worldwide, it undergoes significant shifts influenced by various drivers, challenges, and geographical nuances. The Windsurf Foil Board Market size was valued at  US$ 167.4 Mn in 2024  and is expected to reach  US$ 268.6 Mn by 2031 , growing at a compound annual growth rate  (CAGR) of 7% from 2024 to 2031 Key Takeaways A prominent trend in the Windsurf Foil Board Market Demand is the increasing adoption of foil technology. Foil boards, equipped with hydrofoils beneath the waterline, enable riders to glide effortlessly above the water's surface, providing a thrilling and dynamic experience. This technological innovation has revolutionized the windsurfing landscape, attrac...
Read more

Idiopathic Hypersomnia Treatment Market is Anticipated to Witness High Growth Owing to Increasing Prevalence of Idiopathic Hypersomnia

Image
  Idiopathic Hypersomnia Treatment Market Idiopathic hypersomnia is a neurological sleep disorder characterized by excessive daytime sleepiness and long periods of sleep that does not improve even after long sleep. The treatment of idiopathic hypersomnia is done through medication and behavioral therapies. Medications like psychostimulants, serotonin modulators, wakefulness promoting agents are used to treat the condition and increase wakefulness. The increasing prevalence of idiopathic hypersomnia due to genetic and environmental factors is expected to drive the growth of the idiopathic hypersomnia treatment market. The Global Idiopathic Hypersomnia Treatment Market is estimated to be valued at US$ 389.86 Mn in 2024 and is expected to exhibit a CAGR of 7.3% over the forecast period 2024 to 2030. Key Takeaways Key players operating in the Idiopathic Hypersomnia Treatment Market are Esaote SPA, Epica Animal Health, IDEXX Laboratories, Carestream Health, IMV Imaging, Fujifilm Hold...
Read more

Navigating Opportunities In The Niemann-Pick Disease Drug Type C Treatment Market

Image
  Niemann-Pick Disease Drug Type C Treatment Market Key Takeaways The Niemann-Pick Disease Drug Type C Treatment Market is witnessing significant growth, driven by advancements in medical research and a deeper understanding of the disease pathology. Niemann-Pick Disease Type C (NPC) is a rare genetic disorder characterized by the accumulation of cholesterol and other lipids within cells, leading to progressive neurological and visceral symptoms. With an increasing focus on rare diseases and orphan drug development, the market for NPC treatment is expanding rapidly, offering hope to patients and caregivers. Key players in the pharmaceutical industry are actively investing in research and development to bring novel therapies to market, underscoring the potential for transformative interventions in NPC management. Global Niemann-Pick Disease Drug Type C Treatment Market is estimated to be valued at  US$ 45.40  million  in 2024, and is expected to exhibit a  CAG...
Read more